8-KOther Events

REGENERON PHARMACEUTICALS, INC. 8-K Report (Jan 21, 2003)

Filed January 21, 2003For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed a Current Report (8-K) on January 21, 2003, primarily to disclose the issuance of three press releases on January 7th and January 17th of the same year. While the specific content of these press releases is not detailed within the 8-K itself, their inclusion as exhibits signifies that they contain material information relevant to investors. Investors should review these attached press releases for updates on the company's operations, clinical developments, strategic initiatives, or financial performance. Given the timing and the nature of an 8-K filing, these announcements likely pertain to significant corporate events or developments that occurred around the beginning of January 2003. Investors interested in REGN would need to examine the referenced press releases to understand the substance of these announcements and their potential impact on the company's valuation and future prospects. The filing itself serves as a notification mechanism for these important disclosures.

Key Highlights

  • 1Regeneron Pharmaceuticals (REGN) filed an 8-K on January 21, 2003.
  • 2The filing reports the issuance of two press releases on January 7, 2003.
  • 3The filing also reports the issuance of a press release on January 17, 2003.
  • 4These press releases are attached as exhibits to the 8-K filing.
  • 5The 8-K itself does not contain the specific details of the press releases, only their issuance.
  • 6Investors are directed to review the exhibits for the content of the announcements.
  • 7The filing indicates material information was disclosed to the public around early January 2003.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally report that Regeneron Pharmaceuticals, Inc. issued three press releases on January 7, 2003 (two releases) and January 17, 2003 (one release). These press releases are attached as exhibits.

The specific details of the announcements are contained within the press releases that are included as exhibits (99(a), 99(b), and 99(c)) to this 8-K filing. You would need to access these exhibits to understand the content.

Given that these are press releases filed with the SEC via an 8-K, they likely contain material information such as updates on clinical trials, regulatory milestones, business development activities, strategic partnerships, or significant financial events. The exact nature requires reviewing the exhibits.

This filing is important because it signals that the company has made public disclosures of potentially significant information to the market. Investors should review the content of the attached press releases to assess any impact on the company's business, financial condition, or stock performance.